Beam Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage genetic-medicines company built on base editing — a CRISPR derivative that chemically converts one DNA base into another without cutting both strands of the double helix. That single technical distinction is the entire investment case: classic CRISPR (Cas9) makes a double-strand break and lets the cell repair it, which is efficient for knocking a gene out but messy and risky for correcting a specific mutation. Base editing rewrites the letter in place, which in principle is both more precise and safer (no double-strand-break-associated chromosomal rearrangements). Beam owns the foundational IP via its scientific founders' labs (see Lens 9).

The business runs two delivery modes, which is the right way to understand the company:

• Ex vivo ("edit cells outside the body, then reinfuse") — the risto-cel / BEAM-101 sickle-cell program. Patient stem cells are harvested, base-edited to switch on fetal hemoglobin, and given back after chemo conditioning. This is Beam's near-term commercial asset — BLA submission guided "as early as year-end 2026".
• In vivo ("edit the gene inside the body") — the BEAM-302 (AATD), BEAM-301 (GSD1a), BEAM-304 (PKU) liver programs, delivered by lipid nanoparticle (LNP). This is the bigger, harder, more valuable opportunity — in-vivo editing is the holy grail because it removes the cell-manufacturing bottleneck entirely.

Customers / payers: ultimately health systems and payers for ultra-rare genetic diseases (one-time, multi-million-dollar curative therapies). Suppliers: LNP/lipid suppliers, CDMOs for cell manufacturing, guide-RNA/mRNA synthesis. Partners (the current "revenue"): Pfizer (in-vivo rare disease), Apellis (complement), and a royalty interest in the Lilly/Verve cardiovascular franchise (Lens 4). Contract structure is the standard biotech mix — upfront + milestones + royalties; revenue is lumpy collaboration recognition, not recurring product revenue yet.

Lens 2 · Supply Chain (→ CDMO / manufacturing, per +clinical overlay)

The "supply chain" for a base-editing company is a manufacturing-and-delivery chain, and it bifurcates by modality:

Ex vivo (risto-cel) chain — named stakeholders:

• Apheresis centers / treating hospitals → collect patient CD34+ hematopoietic stem cells.
• Cell-manufacturing (CDMO + internal) → Beam edits the cells ex vivo. Beam built its own North Carolina manufacturing facility (Research Triangle Park) to internalize this — the single most capital-intensive node and the historical bottleneck for all autologous cell therapies.
• Conditioning chemotherapy (busulfan) → standard agents, not Beam-supplied, but a clinical bottleneck (infertility risk, hospitalization) that caps addressable patients — the same drag that has throttled Vertex's Casgevy (Lens 7).
• Risto-cel manufacturing for all BEACON doses was completed as of December 2025 — meaning the manufacturing readiness for the BLA is de-risked.

In vivo (BEAM-302 etc.) chain — named stakeholders:

• Lipid / LNP suppliers → the delivery vehicle. LNP is the chokepoint and the IP battleground for all in-vivo genetic medicine (the same lipid know-how that underpins mRNA vaccines).
• mRNA + guide-RNA synthesis → the editor payload.
• Hospitals → simple IV infusion (vs. the months-long ex-vivo odyssey) — this is why in-vivo is structurally superior commercially.

Single-source / chokepoint flags: LNP delivery IP (industry-wide constraint, litigated across the field); internal cell-manufacturing capacity (Beam's own facility de-risks but also ties up capital); conditioning chemo (a demand bottleneck, not supply). No disclosed single-source supplier crisis as of the latest reporting.

Lens 3 · Competitive Advantages (→ IP / data / platform moat, per +clinical overlay)

The moat is the platform + the IP estate + a first-in-human de-risking event.

1. Foundational base-editing IP. Beam's founders (David Liu, Feng Zhang labs; Lens 9) invented base editing. Beam holds exclusive licenses to the core patent estate from the Broad Institute / Harvard. This is the closest thing to a structural moat in the space — competitors must either license from Beam or invent around it (Prime Medicine's "prime editing" is the around-it bet; RNA editors like Wave route around DNA editing entirely).

2. The BEAM-302 proof-of-concept is a moat-widening event, not just a data point. In March 2026 Beam reported that BEAM-302 achieved "the first-ever clinical in vivo genetic correction of a disease-causing mutation" in living patients. At the 60mg dose, mean steady-state total AAT reached 16.1 µM with all patients above the 11 µM protective threshold for up to 12 months; corrected M-AAT was 94% of circulating AAT with an 84% reduction in mutant Z-AAT. This validates the entire in-vivo base-editing thesis, not just one asset — it is the kind of platform-validation that re-rates the whole company.

3. Bargaining power: Asymmetric. Against partners, Beam has leverage in the rare-disease platform (Pfizer paid $300M upfront; Lens 4). Against payers, leverage is weak-to-negative — ultra-rare one-time therapies face brutal reimbursement friction (the Casgevy/Lyfgenia uptake disaster is the cautionary tale, Lens 7). Against patients/clinicians, the in-vivo IV-infusion profile (no chemo, no cell harvest) is a genuine value advantage if it reaches approval.

Moat durability verdict: Real and IP-anchored, but time-boxed by the patent cliff and by fast-following modalities (RNA editing, siRNA knockdown) that achieve overlapping clinical effect without infringing the DNA-editing estate. The moat protects base editing; it does not protect the treatment of AATD or SCD from being addressed another way.

Lens 4 · Segments (collaboration economics in lieu of product segments)

Beam has no product revenue and therefore no reportable product/geographic segments — n/a, pre-commercial. The economically meaningful "segments" are the collaboration/royalty streams that fund the burn:

• Eli Lilly (via Verve acquisition): the largest near-term contributor. License & collaboration revenue in Q1 2026 was $31.7M, of which ~$25.0M was from the Lilly collaboration. Origin: Lilly acquired Verve Therapeutics in June 2025 for $1.0B cash ($10.50/sh) + up to $3.00/sh CVR ($1.3B total). Verve's PCSK9 cardiovascular program (VERVE-101, later VERVE-102) was built on Beam's base-editing platform — so Beam holds a royalty/economic interest that now sits inside Lilly. This is a clean validation of the platform's out-licensing value.
• Pfizer: exclusive four-year research collaboration on in-vivo base editing for three rare-disease targets (liver, muscle, CNS); $300M upfront (some sources cite a $350M figure for a related/expanded structure) + up to $1.05B milestones. A $500M financing was linked to a Pfizer in-vivo candidate license.
• Apellis: research collaboration on complement-driven diseases, six base-editing programs; $75M deal.

Trend: Collaboration revenue is accelerating — FY2025 revenue $139.7M vs FY2024 $63.5M (+120%); Q1 2026 $31.7M vs Q1 2025 $7.5M (+325%). Cause: the Lilly relationship ramping post-Verve-acquisition. Important caveat: this is milestone/recognition revenue, not a durable commercial annuity — it can stop abruptly when a collaboration concludes. Do not model it as a growing top line.

---

Phase B — Measure performance (swapped to Pipeline + Catalysts per +clinical overlay)

Lens 5 · Pipeline by Phase (the asset table IS the company)

Mechanism note (AATD pleiotropy): BEAM-302's edge is that by correcting the PiZ mutation it addresses both the lung disease (low circulating AAT) and the liver disease (toxic Z-AAT polymer accumulation) — augmentation therapy (Grifols/Takeda plasma-derived AAT) only addresses the lung side. That dual-organ correction is the differentiated profile.

The 2025 portfolio prioritization / restructuring narrowed the company onto risto-cel + the in-vivo liver franchise and extended runway — the right move (Lens 9, Lens 12).

Lens 7 · Catalyst Calendar + Mechanism Comps (swapped from P/E comps)

Catalyst calendar (what de-risks or kills each program, and when):

Mechanism comps (by target/modality — NOT P/E, since pre-revenue):

Sickle cell (risto-cel competes against approved one-time therapies):

• Vertex/CRISPR — Casgevy (exa-cel, CRISPR knockout of BCL11A): approved Dec 2023, $2.2M list price, ~consensus $500M sales by 2026, slow uptake (chemo conditioning, months-long process, payer friction). 30 of 64 infused patients came in Q4 2025 alone — ramp is real but slow.
• bluebird bio — Lyfgenia (lenti gene addition): $3.1M, slower than Casgevy, black-box warning for hematologic malignancy.
• risto-cel differentiation: base editing (no double-strand break), HbF >60% / HbS <40% durable profile pitched as best-in-class efficacy. But it enters a market that has proven commercially disappointing — efficacy is not the bottleneck; access/conditioning is.

AATD (BEAM-302's arena — a crowded modality race):

• Wave Life Sciences — WVE-006: RNA editing (GalNAc AIMer), 71% Z-AAT reduction, M-AAT restoration; FDA feedback expected mid-2026 on accelerated approval; Wave regained full rights from GSK. The most direct fast-follower — achieves overlapping effect without DNA editing.
• Arrowhead/Takeda — fazirsiran: RNAi knockdown of Z-AAT; three Phase 3 trials recruiting — furthest along for the liver manifestation, but knockdown only (doesn't restore functional AAT for the lung).
• Sanofi — efdoralprin alfa: long-acting recombinant AAT augmentation.
• Vertex — VX-864 corrector: discontinued (non-serious rash) — a point for Beam (a credible small-molecule path failed).
• Grifols / Takeda / Kamada: incumbent plasma-derived augmentation (the standard of care BEAM-302 wants to displace).

Comps verdict: valuation multiples are n/a / not meaningful for a pre-revenue editor. The relevant comparison is clinical: BEAM-302 is the only AATD asset that corrects the mutation (dual-organ); the siRNA/RNA-editing field is the real competitive threat on timing, not on mechanism completeness.

Lens 8 · Stock-Price Catalysts (what moves BEAM >5%)

BEAM trades ~$29 with a ~$3.4B market cap (June 5 2026), down enormously from its 2021 peak (>$100+) — the classic gene-editing-sector de-rating of 2022–2024. Pattern of what moves the stock:

• Clinical data prints dominate — BEAM-302 AATD data (the March 2026 in-vivo-correction readout) and BEACON SCD data are the largest movers.
• FDA / regulatory events — the BEAM-201 clinical hold + lift (2022) moved it; the risto-cel BLA + designations are the forward catalysts.
• Financings / partnerships — the Pfizer deal, the $500M financing, the Sixth Street facility, and the Lilly/Verve readthrough.
• Sector beta — BEAM moves hard with the gene-editing complex (Intellia, CRISPR Tx, Prime). Macro rate sensitivity is high (long-duration pre-revenue biotech).

What the pattern reveals: the market reacts almost entirely to binary clinical/regulatory events and runway/financing news — not to "earnings." Sentiment is catalyst-gated, which is exactly why the YE2026 BLA and the BEAM-302 pivotal path are the only things that matter for the next 12–18 months.

---

Phase C — Judge people & books

Lens 9 · Management & Science (+ exclusivity, per +clinical overlay)

CEO — John Evans (since 2017). Track record: early Agios Pharmaceuticals executive (SVP Corporate Development), where he helped initiate the Celgene alliance (>$600M). Agios is a good pedigree — a rigorous, science-led precision-medicine shop. Evans is a corporate-development/dealmaker archetype, not a founding scientist — which fits Beam's reality (the science came from the academic founders; the job is to capitalize and commercialize it). Insider ownership ~1.9% beneficial; direct holdings ~1.05M shares + options/RSUs vesting through 2028.

President — Giuseppe Ciaramella, Ph.D. (drug-development depth). CTO — Manmohan Singh (manufacturing/technical).

Scientific founders — the crown jewels: David R. Liu (Broad/Harvard — invented base editing and prime editing), J. Keith Joung, Feng Zhang (CRISPR pioneer), Nicole Gaudelli, Alexis Komor. This is arguably the strongest academic-founder roster in genetic medicine. The KOL/scientific credibility is a real asset for trial design and regulatory dialogue.

Capital allocation: The defining decision was the 2025 portfolio prioritization / restructuring — cutting lower-priority programs (BEAM-201 deprioritized), focusing on risto-cel + in-vivo liver, and extending runway. This is disciplined capital allocation for a cash-burning platform — the opposite of spreading thin. They have repeatedly raised opportunistically (equity, the $500M financing, the Sixth Street non-dilutive facility) to keep runway ahead of catalysts. ROE/ROIC are deeply negative (pre-revenue) and not a useful management scorecard here — the right metric is runway-to-catalyst discipline, which they've managed well.

Red flags: CEO share sales (e.g., 30,078 shares at $24.58 on Apr 1 2026, ~$739k) are routine Rule 10b5-1, non-discretionary, solely to cover RSU tax withholding — not a discretionary bearish signal; ~$25.4M direct holdings remain. Dilution is the genuine, structural shareholder cost: weighted shares 103.3M (Q1'26) vs 88.0M (Q1'25) — ~17% share growth YoY. That is the price of funding a pre-revenue platform and must be modeled into any return.

Lens 10 · Forensic Red Flags (re-pointed to trial integrity / going-concern / dilution)

For a pre-revenue editor, the forensic lens is less about revenue-recognition games and more about cash, dilution, and trial integrity:

• Cash flow vs. earnings: Net loss Q1 2026 $(94.3)M; FY2025 loss from operations $(383.7)M on R&D of $409.6M. Accumulated deficit $1.736B. Burn ~$345M/yr. This is normal for the stage but means survival depends on capital-markets access — the single biggest non-clinical risk.
• Liquidity / going concern: $1.21B cash + marketable securities at Mar 31 2026 ($288.3M cash + $923.4M securities); runway guided into mid-2029 including the Sixth Street facility (initial $100M drawn, maturity Feb 24 2033; ~$100M more anticipated; broader $500M facility earmarked for the risto-cel launch). No going-concern flag — runway comfortably clears the YE2026 BLA and the BEAM-302 pivotal path. Note the runway language drifted favorably: the 2025 restructuring guided "into 2028"; the Sixth Street facility extended it to "mid-2029" — a real improvement, but watch the assumption that the additional $100M and facility milestones actually land.
• Revenue recognition: Collaboration revenue ($31.7M Q1'26) is lumpy milestone/upfront recognition (Lilly $25M of it). Risk = it can be misread as a "growing business." It is not recurring. Watch for any aggressive upfront-recognition timing in the collaboration accounting — nothing flagged in public reporting.
• Stock-based comp / dilution: ~17% YoY share-count growth (Lens 9). SBC inflates the gap between GAAP loss and cash burn — model dilution explicitly.
• Revenue-vs-receivables / inventory: n/a — pre-commercial, no product inventory or trade receivables of consequence yet.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. Per regulatory/regulatory-findings.md (generated 2026-06-17), 0 SEC findings across LR + AAER for the 2021–2026 window. Caveat: the EDGAR EFTS LR query returned HTTP 500 (server error), so Litigation-Release coverage is degraded, not confirmed-clean — re-run on next refresh. AAER returned cleanly with no hits.
• Item 3 (Legal Proceedings): Not directly retrieved this run (filings not ingested per WAVE constraint; `` quote unavailable). No material litigation surfaced in web search.
• Non-SEC enforcement (FTC/DOJ/FDA/etc.): Web search surfaced no material enforcement actions, consent decrees, fines, or penalties against Beam Therapeutics. The only FDA "negative" historically was the BEAM-201 clinical hold (2022), which was lifted — a routine early-program event, not an enforcement action.
• Verdict: No material regulatory or legal findings — verified via SEC EDGAR EFTS (AAER clean; LR endpoint errored — re-verify), web search, and public reporting as of 2026-06-17. Trial-integrity risk is the forward concern (pivotal AATD design, long-term durability), not a past finding.

---

Phase D — Project & stress-test

Lens 11 · rNPV + Runway-to-Catalyst (swapped from EPS projection per +clinical overlay)

No EPS projection — Beam loses money and will for years; an EPS path is n/a — pre-revenue. The clinical-stage question is twofold: (a) does cash reach the next value-inflection catalyst, and (b) what is the lead asset worth risk-adjusted?

(a) Runway-to-catalyst — the question that actually matters: YES, comfortably. $1.21B + Sixth Street facility → runway into mid-2029. The two value-inflection catalysts — risto-cel BLA (YE2026) and BEAM-302 pivotal data (2027+) — both sit well inside the runway. Beam does not need to raise into a catalyst from a position of weakness, which is the single most important de-risking fact about the financial profile. (Contrast with the typical pre-revenue biotech forced to dilute right before a binary readout.)

(b) rNPV sketch of the two lead assets ``:

BEAM-302 (AATD) — the lead value driver:

• Addressable: severe PiZZ AATD ~60,000–100,000 diagnosed patients across US/EU ``; true diagnosed/treatable pool smaller.
• Peak price: one-time curative, plausibly $1–2M per patient by analogy to Casgevy ($2.2M) ``.
• Even at a modest penetration (say 10–15k cumulative treated over the curve) × ~$1.5M = multi-billion cumulative revenue potential ``.
• Probability of success: in-vivo correction already clinically demonstrated → PoS materially above the typical Phase-1 asset (call it ~35–50% to approval vs. ~10–15% baseline) ``.
• The dual-organ (lung + liver) profile is the differentiator vs. augmentation and vs. knockdown-only competitors.

risto-cel (SCD) — near-term but commercially-constrained:

• The efficacy is best-in-class on paper, but the Casgevy/Lyfgenia uptake disaster caps realistic value — slow access, chemo conditioning, payer friction. rNPV here should be haircut hard for commercial (not clinical) risk. It is more a credibility/commercial-muscle-building asset than a blockbuster.

rNPV verdict: The bulk of intrinsic value sits in BEAM-302 and the in-vivo platform optionality (Pfizer, BEAM-301/304, future programs), not in risto-cel. A ~$3.4B market cap against a validated in-vivo platform + ~$1.2B cash (so EV ~$2.2B) looks reasonable-to-cheap if BEAM-302's pivotal works, and expensive if the AATD pivotal disappoints — a classic binary.

Brier forecast to log (NOT logged here — forecast.ts create is skipped per the unattended-breadth-loop rule): the natural tracked prediction would be "BEAM-302 pivotal AATD program meets its primary endpoint (sustained AAT >11 µM) — p≈0.6" and "risto-cel BLA submitted to FDA by 2026-12-31 — p≈0.75". Log on a deliberate /thesis pass, not in the sweep.

Lens 12 · Bull vs Bear

Bull case. Beam is the platform leader in the safest, most precise form of gene editing, and in March 2026 it did the thing the entire field has been promising for a decade: corrected a disease-causing mutation inside a living human (BEAM-302). That single readout de-risks not one asset but the whole in-vivo franchise (AATD, GSD1a, PKU, the Pfizer targets). It has a near-term commercial shot (risto-cel BLA by YE2026, best-in-class SCD profile, RMAT), a fortress balance sheet (~$1.2B, runway to mid-2029 clearing every key catalyst), validating partners (Pfizer $300M+, a Lilly royalty readthrough via the $1.3B Verve buyout), and the strongest founding-science roster in the sector (Liu, Zhang, Joung). Capital allocation has been disciplined (2025 reprioritization). If BEAM-302's pivotal confirms, this is a multi-billion-dollar in-vivo genetic-medicine franchise that the market is currently pricing at a sub-$2.5B EV.

Bear case (risks that could permanently impair). (1) The AATD modality race is brutal — Wave's RNA editor (FDA feedback mid-2026), Arrowhead/Takeda's fazirsiran (already in three Phase 3s) and Sanofi's long-acting augmentation could reach the market first with good-enough effect, capping BEAM-302's share even if it "wins" on mechanism. (2) Commercial reality of one-time genetic cures is grim — Casgevy/Lyfgenia proved that approval ≠ revenue; chemo conditioning (risto-cel) and payer friction throttle uptake. (3) Dilution is structural — ~17% share growth/yr; even a great outcome is partly competed away by share count. (4) Long-term in-vivo safety — base editing avoids double-strand breaks but off-target editing and durability over years are not yet proven; a late safety signal would be catastrophic. Pre-mortem (18 months out, thesis broke): the most likely failure is not the science — it's that BEAM-302's pivotal is fine but Wave/Arrowhead get to AATD first and the commercial TAM gets carved up, while risto-cel launches into the same slow-uptake wall as Casgevy, and the stock de-rates because the platform validation never converts to revenue on the expected timeline.

Are multiples too high? n/a — no earnings multiple. On EV/validated-platform, ~$2.2B EV is not demanding if you believe the in-vivo franchise; it's all about the pivotal.

Contrarian view (what the market is refusing to see): The consensus is fixated on risto-cel/SCD as "the catalyst." The market may be under-weighting BEAM-302 — the in-vivo AATD asset is the real prize and it just posted the most important data in the company's history, yet the bear narrative is dominated by SCD commercial fears and dilution. If you think in-vivo base editing is the future of genetic medicine, BEAM-302 is the most de-risked clinical validation of that thesis available in the public market, and risto-cel is almost a sideshow.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case: The structural way Beam "makes money" today is selling platform optionality to partners — and that is exactly what a short would attack. Revenue is concentrated in collaboration recognition (Lilly ~$25M of $31.7M in Q1) — when those milestones are recognized, the "revenue growth" stops, and a naive holder who modeled it as a growing top line gets hurt. The moat is weaker than bulls think on the dimension that matters commercially: Beam's IP protects base editing, but AATD and SCD can be addressed by RNA editing (Wave), RNAi (Arrowhead/Takeda), augmentation (Sanofi/Grifols), and CRISPR knockout (Vertex's Casgevy) — none of which need Beam's patents. The most dangerous underestimated competitor is Wave Life Sciences — an RNA editor that gets overlapping AATD efficacy without permanently altering DNA (a safer regulatory story for a chronic disease) and has FDA feedback due mid-2026; if Wave wins the accelerated-approval race, BEAM-302's first-mover economics evaporate. Worst capital-allocation reality: chronic dilution (88M→103M shares YoY) — shareholders fund the science and get diluted for it; the CEO sales are benign but the aggregate SBC is a real drag. Assumptions that must hold for ~$29: (i) BEAM-302 pivotal succeeds, (ii) it reaches AATD market before or alongside the siRNA/RNA-edit cohort, (iii) risto-cel actually sells despite the Casgevy precedent, (iv) capital markets stay open for the next raise. If growth/PoS disappoints 20–30%: an AATD pivotal miss or a "good data but second-to-market" outcome could halve the equity, because the in-vivo franchise carries most of the value. The single scenario that permanently impairs: a long-term off-target or durability safety signal in an in-vivo base-edited patient — it would indict not just BEAM-302 but the entire in-vivo platform and the partner deals. Plausibility: low-to-moderate and unknowable today, which is precisely the risk.

Lens 14 · Management Questions (ordered by information value)

1. BEAM-302 pivotal: what is the agreed primary endpoint and the regulatory bar for accelerated approval in AATD — is sustained AAT >11 µM sufficient, or will FDA require a clinical (lung/liver) outcome, and on what timeline?
2. Competitive timing: Wave (mid-2026 FDA feedback) and Arrowhead/Takeda (Phase 3) are ahead on enrollment in AATD — what is your honest read on order of market entry, and does being second-to-market with a "correction" mechanism still win share?
3. risto-cel commercial: given Casgevy/Lyfgenia's slow uptake, what is your realistic year-1–3 patient-treatment forecast, and what specifically about your access/conditioning approach breaks the bottleneck?
4. Capital plan to mid-2029: what milestone triggers the remaining Sixth Street draws and the $500M facility, and under what scenario would you need additional equity before the next pivotal readout?
5. Conditioning-free (ESCAPE/BEAM-103): how real is the timeline to a chemo-free ex-vivo approach, given that conditioning is the true commercial ceiling for SCD?
6. In-vivo durability: what is the longest patient follow-up showing maintained editing, and what is your evidence that the correction is permanent rather than waning?
7. Off-target safety: what is your most sensitive off-target editing assay, and have you seen any signal in the >50 in-vivo patients dosed to date?
8. Lilly/Verve economics: what is the actual royalty/milestone structure Beam retains on the cardiovascular franchise now inside Lilly, and how should we model it?
9. Pfizer collaboration: which of the three targets is furthest along, and what triggers the next milestone payment?
10. Manufacturing: with your NC facility built, what is the cost-of-goods trajectory for risto-cel, and at what volume does it become gross-margin-positive?
11. Pipeline prioritization: after the 2025 restructuring, what is the next program you would cut if you had to, and what would you accelerate with incremental capital?
12. PKU (BEAM-304) and beyond: what is the strategic logic of adding liver indications faster than you can fund pivotals for the ones you have?
13. Payer strategy: what reimbursement model (CMS outcomes-based, the 33-state Medicaid program) are you building for one-time genetic cures, and who owns it internally?
14. Platform vs. product identity: is Beam ultimately a product company (commercializing risto-cel/BEAM-302) or a platform company (out-licensing to Pfizer/Lilly-types) — and how does that shape the next five years of capital allocation?
15. Patent cliff: when do the foundational base-editing patents begin to expire, and what is your strategy to extend exclusivity as RNA/prime-editing fast-followers mature?

---